Tonix launches first product TONMYA, revenue triples to $6.9M but losses widen to $40M

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read

Key Changes

• high

  TONMYA, the company's first FDA-approved product, launched November 2025 and generated $3.7M in Q1 2026 revenue. Total product revenue rose 183% year-over-year to $6.9M, marking the transition from development-stage to commercial operations.

  MD&A: TONMYA launch and revenue verify on EDGAR →
• high

  Net loss widened 139% to $40.2M despite revenue growth, as R&D spending surged 146% to $18.2M and SG&A expenses nearly tripled to $28.6M. Launch costs (sales/marketing up $11.3M, headcount up $3.9M) outpaced early revenue.

  MD&A: Operating expenses and net loss verify on EDGAR →
• high

  Cash runway extends into early Q2 2027 after raising $22.6M post-quarter, but substantial doubt about going concern remains. Operating cash burn accelerated to $42.3M in Q1 2026 from $16.6M prior year.

  MD&A: Liquidity and going concern verify on EDGAR →